Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125323321 | 12532332 | 1 | I | 20160623 | 20160706 | 20160706 | EXP | GB-MHRA-MIDB-2A4516D9-BFF1-4AE9-901B-6294C251CECC | GB-TEVA-671560ACC | TEVA | 73.00 | YR | F | Y | 0.00000 | 20160706 | PH | GB | GB |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125323321 | 12532332 | 1 | PS | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 15 MILLIGRAM DAILY; IN THE MORNING | Y | U | 77255 | 15 | MG | CAPSULE | QD | ||||
125323321 | 12532332 | 2 | C | ASPIRIN. | ASPIRIN | 1 | 75 MILLIGRAM DAILY; IN THE MORNING | 0 | 75 | MG | DISPERSIBLE TABLET | QD | |||||||
125323321 | 12532332 | 3 | C | RAMIPRIL. | RAMIPRIL | 1 | 0 | 5 | MG | CAPSULE | QD | ||||||||
125323321 | 12532332 | 4 | C | SIMVASTATIN. | SIMVASTATIN | 1 | 40 MILLIGRAM DAILY; AT NIGHT | 0 | 40 | MG | TABLET | QD |
Indications of drugs used
no results found |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125323321 | 12532332 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125323321 | 12532332 | Hypocalcaemia | |
125323321 | 12532332 | Hypomagnesaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125323321 | 12532332 | 1 | 20110719 | 20160504 | 0 |